Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...
STAT11h
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an Africa drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
BioSpace12h
Trump Eyes Steep Cuts to CDC HIV Prevention Program
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Fierce Pharma8d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...